Ovarian cancer is an immunogenic tumour, and immunotherapy is a potential treatment for ovarian cancer [6], where the overall objective remission rate of anti-PD-1 antibody ranges from 10 to 15%, lower than that observed in other cancer types [7, 8]. This evidence concerns the gene PDCD1 and ovarian cancer.